BSE Live
Apr 21, 16:01Prev. Close
134.90
Open Price
135.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 21, 15:55Prev. Close
135.37
Open Price
136.24
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
143.59 (240)
| Cash Flow of Kilitch Drugs (India) (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 40.69 | 23.35 | 19.45 | 13.93 | 7.51 | |
| Net CashFlow From Operating Activities | 15.23 | -1.19 | 6.10 | 5.21 | 6.13 | |
| Net Cash Used In Investing Activities | -41.42 | -10.10 | 6.24 | -16.08 | -5.35 | |
| Net Cash Used From Financing Activities | 15.65 | 11.40 | 3.04 | 7.55 | 2.27 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -10.54 | 0.11 | 15.39 | -3.32 | 3.05 | |
| Cash And Cash Equivalents Begin of Year | 17.95 | 17.84 | 2.45 | 5.77 | 2.72 | |
| Cash And Cash Equivalents End Of Year | 7.41 | 17.95 | 17.84 | 2.45 | 5.77 |
26.11.2025
Kilitch Drugs Consolidated September 2025 Net Sales at Rs 48.92 crore, up 3.05% Y-o-Y
24.11.2025
Kilitch Drugs Standalone September 2025 Net Sales at Rs 37.81 crore, down 16.62% Y-o-Y
20.05.2025
Kilitch Drugs Consolidated March 2025 Net Sales at Rs 61.23 crore, up 36.61% Y-o-Y
20.05.2025
Kilitch Drugs Standalone March 2025 Net Sales at Rs 56.30 crore, up 43.87% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth